These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30231723)

  • 1. Reconciling States' "Right to Try" Legislation and FDA's Expanded Access Program: Legal Issues.
    Shapiro RS
    Ther Innov Regul Sci; 2017 Mar; 51(2):153-156. PubMed ID: 30231723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program.
    Speers MA
    Pharmaceut Med; 2019 Apr; 33(2):89-98. PubMed ID: 31933253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Right to Try Act.
    Agarwal R; Saltz LB
    Clin Cancer Res; 2020 Jan; 26(2):340-343. PubMed ID: 31666248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RxLegal: A Rapid Review of Right-To-Try.
    Gabay M
    Hosp Pharm; 2018 Jul; 53(4):234-235. PubMed ID: 30038441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Congress Get 'Right to Try' Right?
    Kirkner RM
    Manag Care; 2018 May; 27(5):10-11. PubMed ID: 29763399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to Try.
    Chapman CR; Belli HM; Leach D; Shah LD; Bateman-House A
    Med Access Point Care; 2021; 5():23992026211005991. PubMed ID: 36204503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of FDA's Expanded Access Program for Investigational Drugs.
    Jarow JP; Lurie P; Ikenberry SC; Lemery S
    Ther Innov Regul Sci; 2017 Mar; 51(2):177-179. PubMed ID: 28553565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded Access and Right To Try Requests: The Community Oncologist's Experience.
    Zettler ME; Jeune-Smith Y; Feinberg BA; Phillips EG; Gajra A
    JCO Oncol Pract; 2021 Nov; 17(11):e1719-e1727. PubMed ID: 33886355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
    Chapman CR; Eckman J; Bateman-House AS
    Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
    Smith C; Stout J; Adjei AA; Buckner J; Wentworth M; Tilburt J; Master Z
    J Natl Cancer Inst; 2021 Jun; 113(6):735-741. PubMed ID: 32882030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 15. Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the "Right to Try".
    Van Norman GA
    JACC Basic Transl Sci; 2018 Apr; 3(2):280-293. PubMed ID: 30062214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncology Expanded Access and FDA's Project Facilitate.
    Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R
    Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient advocacy organizations' information for patients on pre-approval access to investigational treatments.
    Folkers KM; Leone S; Caplan A
    BMC Res Notes; 2019 Oct; 12(1):706. PubMed ID: 31661023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who Stands to Benefit? Right to Try Law Provisions and Implications.
    Kearns L; Bateman-House A
    Ther Innov Regul Sci; 2017 Mar; 51(2):170-176. PubMed ID: 30231728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Federal Right to Try: Where Is It Going?
    Folkers K; Chapman C; Redman B
    Hastings Cent Rep; 2019 Mar; 49(2):26-36. PubMed ID: 30998281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Negligence Determinations, the "Right to Try," and Expanded Access to Innovative Treatments.
    Meyerson D
    J Bioeth Inq; 2017 Sep; 14(3):385-400. PubMed ID: 28634770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.